Bcl-3 promotes proliferation and chemosensitivity in BL1 subtype of TNBC cells  

作　　者：Junhaohui Huo Xi Chen Haohao Zhang Yiming Hu Yuhang Jiang Sanhong Liu Xiaoren Zhang 

机构地区：[1]Key Laboratory of Stem Cell Biology,Shanghai Jiao Tong University School of Medicine (SJTUSM)& Shanghai Institutes for Biological Sciences (SIBS),Chinese Academy of Sciences (CAS),Shanghai 200031,China [2]Department of Orthopedics,Shanghai Key Laboratory of Orthopedic Implants,Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine,Shanghai 200011,China [3]Shanghai Institute of Advanced Immunochemical Studies,ShanghaiTech University,Shanghai 201210,China

出　　处：《Acta Biochimica et Biophysica Sinica》2018年第11期1141-1149,共9页生物化学与生物物理学报（英文版）

基　　金：the grants from the National Basic Research Program (Nos.2014CB541904 and 2014CB943600);the National Natural Science Foundation of China (Nos.31570902 and 31370881).

摘　　要：Bcl-3 is an established oncogene in diverse malignant tumors.In this study,we investigated a dual role of Bcl-3 in BLl-subtype triple-negative breast cancer (TNBC).The BL1-subtype TNBC is featured by increasing cell cycle gene expression and the highest sensitivity to chemotherapy among all subtypes.Bcl-3 is associated with a better prognosis in BL1 patients.Bcl-3 knockdown in BL1 cell MDA-MB-468 induces the inhibition of cell proliferation and the G1/S transition arrest by promoting p27 and reducing the expressions of c-Myc and skp2 at mRNA and protein levels. Meanwhile,Bcl-3 enhances the sensitivity of MDA-MB-468 to chemotherapeutics ABX and PTX. Furthermore,the regulation mechanisms are restricted to BL1 cell and do not occur in SUM159PT, a typical MSL subtype of TNBC cell.These data suggest that Bcl-3 may be a potential clinical biomarker for diagnosis,treatment,and prognosis of patients with BL1-subtype TNBC.

关 键 词：TNBC BL1 SUBTYPE Bcl-3 PROLIFERATION CHEMOSENSITIVITY 

分 类 号：Q[生物学]